• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Announces New Regional Leadership

    6/18/26 4:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    The appointments strengthen the company's leadership pipeline as it moves towards a smoke‑free future

    Philip Morris International (PMI) (NYSE:PM) announced a series of regional leadership appointments that support its ongoing shift toward a smoke‑free future.

    Effective August 1, 2026, Marco Hannappel has been appointed President, Europe Region, and Can Kuterdem has been appointed President, Latin America & Canada Region. These appointments build on PMI's evolved organizational model announced in late 2025, under which Gijs de Best serves as President, South Asia, Indochina, CIS & Middle East & Africa Region, and Vassilis Gkatzelis continues as President East & Southeast Asia, Pacific and PMI Global Travel Retail Region. The four regional presidents report to Frederic de Wilde - CEO of the International Business Unit of PMI and are the key operational leaders for the unit that generates the large majority of total PMI net revenues.

    Marco Hannappel takes over the role of President, Europe Region, succeeding Massimo Andolina, who was recently announced as PMI's Group Chief Financial Officer, both effective August 1, 2026.

    Hannappel brings extensive international experience and a strong track record in leading business growth across complex and highly regulated markets. Since joining the company in 2019 as President and Managing Director Italy, he has held several senior leadership roles of increasing responsibility. He later served as Area Vice President Southwest Europe, managing Italy and Iberia, and most recently, as President of the Latin America & Canada Region.

    Can Kuterdem is appointed President, Latin America & Canada Region, effective August 1, 2026, succeeding Marco Hannappel.

    Kuterdem is a seasoned business leader with strong general management experience and a people-centric leadership approach. Most recently, as Managing Director, Poland, he transformed one of Philip Morris International's largest European markets into a multi-category business, driving growth and strengthening organizational engagement. Previously, he served as Vice President Strategy & Program Delivery, Europe Region, where he played a central role in shaping the regional strategy and leading a more integrated approach to execution of business-critical initiatives across markets.

    Before joining the company in 2020, he built an international career in consulting and technology, including The Boston Consulting Group and Samsung, where he held senior leadership roles across multiple regions.

    Gijs de Best was appointed President, South Asia, Indochina, CIS & Middle East & Africa Region in January 2026. He brings more than 20 years of leadership experience at the company, with a strong track record of driving business performance through consumer-centricity and a passion for developing teams. He began his career at PMI in 2004 as a financial analyst in the Netherlands and has since held a range of increasingly senior roles across multiple markets and regions, most recently as President, Philippines, and Vice President Strategy & Program Delivery.

    Vassilis Gkatzelis continues as President, East & Southeast Asia, Pacific and PMI Global Travel Retail Region, a role he assumed in 2024, with expanded accountabilities for Southeast Asia as of 2026. He oversees a diverse set of markets spanning developed and developing economies, alongside the Global Travel Retail business.

    Since joining the company in 2003, Gkatzelis has held a wide range of strategic and operational leadership roles across Europe, the Middle East & Africa, Asia Pacific and the Global Operations Center in Switzerland. He brings a strong track record leading business transformation at scale, and building high-performing organizations, with a focus on external engagement and talent development. Prior to his current role, he served as President Director of PT HM Sampoerna Tbk., PMI's affiliate listed on the Indonesia Stock Exchange, as well as Managing Director of Egypt & Levant Cluster, where he led the build-up and scaling of the smoke-free business.

    These appointments reflect Philip Morris International's continued focus on strengthening leadership capabilities as a leading global consumer goods company. Earlier in 2026 Philip Morris International evolved its organizational model and implemented two new primary business units in addition to its wellness unit Aspeya, reporting to Group CEO PMI Jacek Olczak - PMI International under the leadership of Frederic de Wilde, CEO PMI International, and PMI U.S. – under the leadership of Stacey Kennedy, CEO PMI U.S.

    Philip Morris International: A Global Smoke-Free Champion

    Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch, and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 43% of PMI's first-quarter 2026 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260618517768/en/

    Philip Morris International

    Corey Henry

    T: +1 (202) 679 7296

    E: corey.henry@pmi.com

    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/22/2026$216.00Buy
    BTIG Research
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    More analyst ratings

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    7/22/26 7:02:12 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    7/9/26 4:05:53 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Other Events

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    6/29/26 4:05:25 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Combes Michel was granted 1,119 shares, increasing direct ownership by 11% to 11,643 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:23 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Geissler Werner was granted 1,119 shares, increasing direct ownership by 1% to 98,356 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:18 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morparia Kalpana was granted 1,119 shares, increasing direct ownership by 4% to 28,236 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:11 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Philip Morris International with a new price target

    BTIG Research initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $216.00

    7/22/26 8:02:41 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;

    Second-Quarter Reported Diluted EPS declined by 7.7% to $1.80; Adjusted Diluted EPS grew by 15.2% to $2.20; and by 13.6% excluding currency; Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2026 second quarter results.1 "We delivered outstanding results in the second quarter, driving net revenues to over $11 billion for the first time with excellent growth across all headline metrics," said Jacek Olczak, Group CEO PMI. "With a robust first half under our belt, including continued momentum and strong results in our smoke-free business, we are well positioned to deliver on our full-year targets while investing for future growth." _______________

    7/22/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Host Webcast of 2026 Second-Quarter and First Six-Months Results

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast on Wednesday, July 22, 2026, at 9:00 a.m. ET, to discuss its 2026 second-quarter and first six-months financial results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast can be accessed here. The webcast will be hosted by Emmanuel Babeau, Group Chief Financial Officer, and Massimo Andolina, incoming Group CFO, and will include discussion of PMI’s financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI’s Investor Relations App at www.pmi.com

    7/15/26 10:02:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    PMI U.S. Unveils the ZYN America250 Art Series, Bringing Modern Culture to Limited-Edition Cases

    Featuring original designs from acclaimed artists, the nationwide initiative celebrates America's 250th anniversary through collectible metal ZYN cases STAMFORD, Conn., July 3, 2026 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) today announced the launch of the ZYN America250 Art Series, a cultural initiative from America's No. 1 nicotine pouch brand, celebrating the nation's 250th anniversary through the lens of contemporary American art and creative expression. The ZYN America250 Art Series brings together a curated group of American and U.S.-based a

    7/3/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    PMI U.S. Expands Its Talent Pipeline and Welcomes New Class of Interns Across the Enterprise

    Intern class doubles to 25, signaling expanded investment in early-career talent STAMFORD, Conn., May 18, 2026 /PRNewswire/ -- Today, Philip Morris International's U.S. business (PMI U.S.) announced expanded internship and early‑career programs across the organization, underscoring its commitment to developing the next generation of talent to grow the business and innovate its industry. The programs are designed to provide meaningful experience, exposure, and opportunity for students just beginning their careers and early-career professionals ready to accelerate their impact. This summer, PMI U.S. will welcome its second intern

    5/18/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;

    Second-Quarter Reported Diluted EPS declined by 7.7% to $1.80; Adjusted Diluted EPS grew by 15.2% to $2.20; and by 13.6% excluding currency; Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2026 second quarter results.1 "We delivered outstanding results in the second quarter, driving net revenues to over $11 billion for the first time with excellent growth across all headline metrics," said Jacek Olczak, Group CEO PMI. "With a robust first half under our belt, including continued momentum and strong results in our smoke-free business, we are well positioned to deliver on our full-year targets while investing for future growth." _______________

    7/22/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on July 20, 2026, to shareholders of record as of June 25, 2026. The ex-dividend date is June 25, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily cons

    6/11/26 6:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Participates in 2026 dbAccess Global Consumer Conference; Updates 2026 Full-Year Diluted EPS Forecast for Currency and Non-Cash Impairment Only

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, will address investors today at the 2026 dbAccess Global Consumer Conference in Paris at 11:15 a.m. CET (5:15 a.m. ET), including discussion of the following topics: PMI's continued expectation of a strong full-year performance, notably driven by the broad-based momentum of our international multicategory smoke-free business, led by IQOS. Recent heat-not-burn category developments broadly in-line with our expectations, most notably in Japan following the April 1, 2026 excise tax increase, with April offtake impacted by consumer pantry de-loading and IQOS maintaining a strong category sh

    6/2/26 1:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care